{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:39Z","timestamp":1791924759996,"version":"4.3.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The emergence of immune checkpoint inhibitors (ICIs) has significantly prolonged the survival time of cancer patients. However, it may also lead to various immune-related adverse events (irAEs), including Guillain\u2013Barr\u00e9 syndrome (GBS), a rare type of irAE. Most GBS patients can recover spontaneously due to the self-limited nature of the disease, but severe cases can result in respiratory failure or even death. Here we report a rare case of GBS occurring in a 58-year-old male patient with non-small cell lung cancer (NSCLC) who developed muscle weakness and numbness of the extremities during chemotherapy combined with KN046, a PD-L1\/CTLA-4 bispecific antibody. Despite receiving methylprednisolone and \u03b3-globulin, the patient\u2019s symptoms did not improve. However, there was significant improvement after treatment with mycophenolate mofetil (MM) capsules, which is not a routine regimen for GBS. To the best of our knowledge, this is the first reported case of ICIs-induced GBS that responded well to mycophenolate mofetil instead of methylprednisolone or \u03b3-globulin. Thus, it provides a new treatment option for patients with ICIs-induced GBS.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1132692","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T04:29:30Z","timestamp":1683520170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Case Report: ICIs-induced Guillain\u2013Barr\u00e9 syndrome recovered from mycophenolate mofetil"],"prefix":"10.3389","volume":"14","author":[{"given":"Mengge","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiguang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangbo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7722","article-title":"Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis","volume":"5","author":"Farooq","year":"","journal-title":"JAMA Netw Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 Syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"","journal-title":"Nat Rev Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11910-020-01038-2","article-title":"Neurologic toxicities of cancer immunotherapies: a review","volume":"20","author":"Harrison","year":"","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101535","article-title":"Toxicity spectrum of immunotherapy in advanced lung cancer: a safety analysis from clinical trials and a pharmacovigilance system","volume":"50","author":"Yan","year":"","journal-title":"EClinicalMedicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102189","article-title":"Neurological complications of cancer immunotherapy","volume":"97","author":"Roth","year":"","journal-title":"Cancer Treat Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03514-8","article-title":"Neurological adverse effects due to programmed death 1 (PD-1) inhibitors","volume":"148","author":"Shi","year":"","journal-title":"J Neurooncol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13081","article-title":"Immune checkpoint inhibitors: new strategies to checkmate cancer","volume":"191","author":"Wilson","year":"","journal-title":"Clin Exp Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 Syndrome","volume":"397","author":"Shahrizaila","year":"","journal-title":"Lancet Lond Engl"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the national influenza immunization program, united states, 1976\u20131977","volume":"110","author":"Schonberger","year":"","journal-title":"Am J Epidemiol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380214","article-title":"Acute axonal Guillain-Barr\u00e9 syndrome with IgG antibodies against motor axons following parenteral gangliosides","volume":"38","author":"Illa","year":"","journal-title":"Ann Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09742-2","article-title":"Axonal variants of Guillain-Barr\u00e9 syndrome: an update","volume":"268","author":"Shang","year":"","journal-title":"J Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50946","article-title":"Antecedent infections in Guillain-Barr\u00e9 syndrome: a single-center, prospective study","volume":"6","author":"Hao","year":"","journal-title":"Ann Clin Transl Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg207","article-title":"Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barr\u00e9 syndrome","volume":"126","author":"Wanschitz","year":"","journal-title":"Brain J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000230","article-title":"Severe relapse of vaccine-induced Guillain-Barr\u00e9 syndrome after treatment with nivolumab","volume":"20","author":"Yuen","year":"","journal-title":"J Clin Neuromuscul. Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.750507","article-title":"Mechanisms of chemotherapy-induced neurotoxicity","volume":"13","author":"Was","year":"2022","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aex229","article-title":"Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review","volume":"119","author":"Flatters","year":"","journal-title":"Br J Anaesth."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200411000-00010","article-title":"Guillain-Barr\u00e9 Syndrome in a patient with metastatic colon cancer receiving oxaliplatin-based chemotherapy","volume":"15","author":"Christodoulou","year":"","journal-title":"Anticancer. Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26158","article-title":"Guillain-Barr\u00e9-Like syndrome from esophageal squamous cell carcinoma","volume":"14","author":"Jordan","year":"","journal-title":"Cureus"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000364","article-title":"Immune checkpoint inhibitor-related Guillain-Barr\u00e9 syndrome: a case series and review of the literature","volume":"44","author":"Janssen","year":"","journal-title":"J Immunother. Hagerstown Md 1997"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027351","article-title":"Efficacy of therapies in the treatment of Guillain-barre syndrome: a network meta-analysis","volume":"100","author":"Lin","year":"","journal-title":"Med (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.908282","article-title":"Acupuncture treatment of Guillain\u2013Barr\u00e9 syndrome after using immune checkpoint inhibitors: a case report","volume":"13","author":"Xu","year":"2022","journal-title":"Front Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.102731","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with mycophenolate mofetil: a pilot study","volume":"78","author":"Garssen","year":"","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10404-0","article-title":"Guillain\u2013Barr\u00e9 Syndrome in patients treated with immune checkpoint inhibitors","volume":"268","author":"Fan","year":"","journal-title":"J Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1132692\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T04:29:33Z","timestamp":1683520173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1132692\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2023.1132692"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1132692","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"article-number":"1132692"}}